📊 CARL Key Takeaways
Is Carlsmed, Inc.. (CARL) a Good Investment?
CARL demonstrates strong top-line momentum with 85.9% revenue growth and industry-leading 77.1% gross margins, but faces critical profitability challenges with -57.6% operating margins and -13M negative operating cash flow. The company's strong balance sheet (73M cash, 0.17x D/E) provides 5-6 years of runway, but path to profitability remains unproven and represents the primary execution risk.
CARLSMED is delivering very strong top-line growth and maintains an unusually strong cash position with low leverage, which gives it time to scale its platform. However, the business is still deeply unprofitable, with severely negative operating and free cash flow margins, so the core fundamental question is whether revenue growth can translate into materially better operating leverage. The company’s fundamentals support patience rather than outright conviction until loss compression becomes clearer.
Why Buy Carlsmed, Inc.. Stock? CARL Key Strengths
- Exceptional revenue growth of 85.9% YoY demonstrates strong product-market fit in surgical instruments sector
- Industry-leading gross margin of 77.1% indicates efficient manufacturing and robust unit economics at the product level
- Fortress balance sheet with 73M cash, minimal debt (0.17x D/E), and 11.88x current ratio provides financial flexibility to invest in growth and weather operational challenges
- Revenue growth is exceptionally strong at +85.9% YoY, indicating rising commercial adoption
- Gross margin of 75.3% suggests an attractive product mix and solid underlying unit economics before operating expenses
- Balance sheet is strong with $85.79M in cash, an 8.87x current ratio, and low debt-to-equity of 0.16x
CARL Stock Risks: Carlsmed, Inc.. Investment Risks
- Severe operating losses (-9.3M) and negative net income (-8.7M) indicate core business operations are unprofitable and not scalable at current structure
- Negative operating cash flow (-13M) and -81.2% FCF margin reveals cash burn despite positive revenues; company loses 81 cents in cash for every dollar earned
- Unsustainably high operating expenses relative to revenue scale: 77.1% gross margin collapses to -57.6% operating margin, suggesting R&D/SG&A expenses exceed revenue by 134.7% of sales
- Cash sustainability: 73M reserves consumed at 13M annually provides only ~5.6 year runway before depletion if losses persist
- Operating margin of -60.5% and net margin of -58.7% show the company is still far from sustainable profitability
- Free cash flow of -$29.62M and negative operating cash flow indicate continued cash burn
- Negative returns on equity and assets suggest capital is not yet being converted into efficient earnings growth
Key Metrics to Watch
- Operating cash flow and FCF margin trajectory - critical inflection toward positive cash generation
- Operating expense ratio as percentage of revenue - evidence of margin expansion discipline as revenue scales
- Gross margin stability - confirm manufacturing efficiency holds with higher volume
- Cash burn rate and months of cash remaining - monitor runway depletion rate monthly
- Operating expense growth relative to revenue growth, especially sales and marketing and R&D leverage
- Quarterly free cash flow burn and cash runway versus progress in operating margin improvement
Carlsmed, Inc.. (CARL) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 11.88x current ratio provides a solid financial cushion.
CARL Profit Margin, ROE & Profitability Analysis
CARL vs Healthcare Sector: How Carlsmed, Inc.. Compares
How Carlsmed, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Carlsmed, Inc.. Stock Overvalued? CARL Valuation Analysis 2026
Based on fundamental analysis, Carlsmed, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Carlsmed, Inc.. Balance Sheet: CARL Debt, Cash & Liquidity
CARL Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Carlsmed, Inc..'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-6.11 indicates the company is currently unprofitable.
CARL Revenue Growth, EPS Growth & YoY Performance
CARL Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $10.2M | -$5.7M | $-0.32 |
| Q3 2025 | $6.6M | -$5.4M | $-0.40 |
| Q2 2025 | $6.1M | -$5.4M | $-1.47 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Carlsmed, Inc.. Dividends, Buybacks & Capital Allocation
CARL SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Carlsmed, Inc.. (CIK: 0001794546)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CARL
What is the AI rating for CARL?
Carlsmed, Inc.. (CARL) has a Combined AI Rating of HOLD from Claude (HOLD) and ChatGPT (HOLD) with 70% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CARL's key strengths?
Claude: Exceptional revenue growth of 85.9% YoY demonstrates strong product-market fit in surgical instruments sector. Industry-leading gross margin of 77.1% indicates efficient manufacturing and robust unit economics at the product level. ChatGPT: Revenue growth is exceptionally strong at +85.9% YoY, indicating rising commercial adoption. Gross margin of 75.3% suggests an attractive product mix and solid underlying unit economics before operating expenses.
What are the risks of investing in CARL?
Claude: Severe operating losses (-9.3M) and negative net income (-8.7M) indicate core business operations are unprofitable and not scalable at current structure. Negative operating cash flow (-13M) and -81.2% FCF margin reveals cash burn despite positive revenues; company loses 81 cents in cash for every dollar earned. ChatGPT: Operating margin of -60.5% and net margin of -58.7% show the company is still far from sustainable profitability. Free cash flow of -$29.62M and negative operating cash flow indicate continued cash burn.
What is CARL's revenue and growth?
Carlsmed, Inc.. reported revenue of $16.1M.
Does CARL pay dividends?
Carlsmed, Inc.. does not currently pay dividends.
Where can I find CARL SEC filings?
Official SEC filings for Carlsmed, Inc.. (CIK: 0001794546) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CARL's EPS?
Carlsmed, Inc.. has a diluted EPS of $-0.32.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is CARL a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Carlsmed, Inc.. has a HOLD rating with 70% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is CARL stock overvalued or undervalued?
Valuation metrics for CARL: ROE of -9.4% (sector avg: 15%), net margin of -54.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy CARL stock in 2026?
Our dual AI analysis gives Carlsmed, Inc.. a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CARL's free cash flow?
Carlsmed, Inc..'s operating cash flow is $-13.0M, with capital expenditures of $79.0K. FCF margin is -81.2%.
How does CARL compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -54.0% (avg: 12%), ROE -9.4% (avg: 15%), current ratio 11.88 (avg: 2).